KR101552033B1 - 약학 조성물 - Google Patents

약학 조성물 Download PDF

Info

Publication number
KR101552033B1
KR101552033B1 KR1020137027051A KR20137027051A KR101552033B1 KR 101552033 B1 KR101552033 B1 KR 101552033B1 KR 1020137027051 A KR1020137027051 A KR 1020137027051A KR 20137027051 A KR20137027051 A KR 20137027051A KR 101552033 B1 KR101552033 B1 KR 101552033B1
Authority
KR
South Korea
Prior art keywords
water
weight
content
tablet
oral preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020137027051A
Other languages
English (en)
Korean (ko)
Other versions
KR20130122019A (ko
Inventor
가즈유키 후지하라
Original Assignee
다이닛본 스미토모 세이야꾸 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37452103&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101552033(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 다이닛본 스미토모 세이야꾸 가부시끼가이샤 filed Critical 다이닛본 스미토모 세이야꾸 가부시끼가이샤
Publication of KR20130122019A publication Critical patent/KR20130122019A/ko
Application granted granted Critical
Publication of KR101552033B1 publication Critical patent/KR101552033B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020137027051A 2005-05-26 2006-05-26 약학 조성물 Expired - Lifetime KR101552033B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005153508 2005-05-26
JPJP-P-2005-153508 2005-05-26
PCT/JP2006/310571 WO2006126681A1 (ja) 2005-05-26 2006-05-26 医薬品組成物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020077027270A Division KR101380088B1 (ko) 2005-05-26 2006-05-26 약학 조성물

Publications (2)

Publication Number Publication Date
KR20130122019A KR20130122019A (ko) 2013-11-06
KR101552033B1 true KR101552033B1 (ko) 2015-09-09

Family

ID=37452103

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020137027051A Expired - Lifetime KR101552033B1 (ko) 2005-05-26 2006-05-26 약학 조성물
KR1020077027270A Expired - Lifetime KR101380088B1 (ko) 2005-05-26 2006-05-26 약학 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020077027270A Expired - Lifetime KR101380088B1 (ko) 2005-05-26 2006-05-26 약학 조성물

Country Status (22)

Country Link
US (5) US8729085B2 (cg-RX-API-DMAC10.html)
EP (2) EP1884242B1 (cg-RX-API-DMAC10.html)
JP (2) JP4733120B2 (cg-RX-API-DMAC10.html)
KR (2) KR101552033B1 (cg-RX-API-DMAC10.html)
CN (2) CN101184489B (cg-RX-API-DMAC10.html)
AU (1) AU2006250340C1 (cg-RX-API-DMAC10.html)
BE (1) BE2014C057I2 (cg-RX-API-DMAC10.html)
BR (2) BR122020005056B1 (cg-RX-API-DMAC10.html)
CA (1) CA2606510C (cg-RX-API-DMAC10.html)
CY (2) CY1114118T1 (cg-RX-API-DMAC10.html)
DK (2) DK1884242T3 (cg-RX-API-DMAC10.html)
ES (2) ES2408687T3 (cg-RX-API-DMAC10.html)
FR (1) FR14C0069I2 (cg-RX-API-DMAC10.html)
HU (1) HUS1400051I1 (cg-RX-API-DMAC10.html)
LU (1) LU92550I2 (cg-RX-API-DMAC10.html)
MX (1) MX2007014872A (cg-RX-API-DMAC10.html)
NL (1) NL300690I2 (cg-RX-API-DMAC10.html)
PL (1) PL1884242T3 (cg-RX-API-DMAC10.html)
PT (1) PT1884242E (cg-RX-API-DMAC10.html)
RU (1) RU2398586C3 (cg-RX-API-DMAC10.html)
SI (1) SI1884242T1 (cg-RX-API-DMAC10.html)
WO (1) WO2006126681A1 (cg-RX-API-DMAC10.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101435199B1 (ko) 2005-05-18 2014-08-28 다이닛본 스미토모 세이야꾸 가부시끼가이샤 드록시도파를 함유하는 안정한 정제
SI1884242T1 (sl) 2005-05-26 2013-07-31 Dainippon Sumitomo Pharma Co., Ltd. Farmacevtski sestavek, ki vsebuje lurazidon
WO2009101940A1 (ja) * 2008-02-11 2009-08-20 Dainippon Sumitomo Pharma Co., Ltd. 溶出性の改善された錠剤
WO2009151072A1 (ja) * 2008-06-13 2009-12-17 大日本住友製薬株式会社 口腔内速崩壊錠及びその製造方法
CN102170912A (zh) * 2008-09-30 2011-08-31 大洋药品工业株式会社 压缩成型制剂及其制造方法
EP3351240B1 (en) 2009-05-19 2019-04-10 Celgene Corporation Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
US9469630B2 (en) * 2010-10-18 2016-10-18 Sumitomo Dainippon Pharma Co., Ltd. Sustained-release formulation for injection
WO2012063246A1 (en) * 2010-11-11 2012-05-18 Mapi Pharma Ltd. Amorphous form of lurasidone hydrochloride
WO2012107890A2 (en) * 2011-02-10 2012-08-16 Ranbaxy Laboratories Limited Crystalline forms of lurasidone hydrochloride
US9433620B2 (en) * 2011-05-13 2016-09-06 Cadila Healthcare Limited Pharmaceutical compositions of lurasidone
EP2736905A4 (en) 2011-07-28 2015-07-29 Mapi Pharma Ltd INTERMEDIATE COMPOUNDS AND PROCESS FOR THE PREPARATION OF LURASIDONE AND SALTS THEREOF
CN102911169B (zh) * 2011-08-02 2015-05-06 上海医药工业研究院 一种卢拉西酮的制备方法
US20140243383A1 (en) 2011-08-24 2014-08-28 Cadila Healthcare Limited Pharmaceutical compositions of silodosin
CN103446071B (zh) * 2012-05-29 2017-12-19 江苏豪森药业集团有限公司 一种口服片剂及其制备方法和用途
CN102688209A (zh) * 2012-06-21 2012-09-26 李兴惠 鲁拉西酮片和制备方法
CN102688210A (zh) * 2012-06-21 2012-09-26 李兴惠 鲁拉西酮的药物组合物和制备方法
CN106074414B (zh) * 2012-07-12 2019-01-18 成都康弘药业集团股份有限公司 一种含有鲁拉西酮的口腔崩解片及其制备方法
CN103006661B (zh) * 2012-12-06 2015-02-18 江苏先声药物研究有限公司 一种含有盐酸鲁拉西酮的制剂及其制备方法
US20150157628A1 (en) * 2013-12-11 2015-06-11 Saravanan Kannusamy Pharmaceutical compositions of Lurasidone and Process for preparation thereof
WO2016012898A1 (en) * 2014-07-25 2016-01-28 Lupin Limited Oral pharmaceutical composition of lurasidone
CN104606133A (zh) * 2015-01-07 2015-05-13 万特制药(海南)有限公司 鲁拉西酮口服混悬液及其制备方法
WO2016139683A2 (en) * 2015-03-05 2016-09-09 Jubilant Generics Limited Pharmaceutical compositions of lurasidone and process for preparing the same
DE102016205950A1 (de) * 2016-04-08 2017-10-12 Dietrich Seidel Mittel zur Verwendung bei entzündlichen Zuständen der Schleimhäute
EA201991007A1 (ru) * 2016-11-02 2019-08-30 Сановель Илач Санайи Ве Тиджарет А.Ш. Твердые фармацевтические композиции на основе гидрохлорида луразидона для перорального применения
CN108567758A (zh) * 2017-03-08 2018-09-25 湖南洞庭药业股份有限公司 盐酸鲁拉西酮片剂及其制备方法
SG11202001436YA (en) * 2017-08-18 2020-03-30 Abbvie Inc Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis
CN107875122A (zh) * 2017-12-17 2018-04-06 佛山市弘泰药物研发有限公司 一种盐酸鲁拉西酮自微乳制剂及其制备方法
CN107854445A (zh) * 2017-12-17 2018-03-30 佛山市弘泰药物研发有限公司 一种盐酸鲁拉西酮分散片及其制备方法
CN107854446A (zh) * 2017-12-19 2018-03-30 佛山市弘泰药物研发有限公司 一种盐酸鲁拉西酮口崩片及其制备方法
JPWO2019167978A1 (ja) 2018-02-28 2021-02-04 大日本住友製薬株式会社 溶出が制御された水性懸濁型医薬製剤
EP3772993A1 (de) 2018-04-10 2021-02-17 Z-Catering Mitte GmbH Vorrichtung zur aufwärmung von in verpackungseinheiten konserviereten speisen und zum bereitstellen von gemeinschaftsverpflegung
WO2019199134A1 (ko) * 2018-04-13 2019-10-17 주식회사 삼양바이오팜 레날리도마이드를 포함하는 약제학적 조성물
JP6905781B1 (ja) * 2019-09-25 2021-07-21 ノーベルファーマ株式会社 不快な味がマスクされた顆粒剤及びその製造方法
WO2022042646A1 (zh) * 2020-08-26 2022-03-03 浙江华海药业股份有限公司 盐酸鲁拉西酮组合物及其制备方法
AT17300U3 (de) * 2020-12-03 2022-02-15 G L Pharma Gmbh Feste orale pharmazeutische Zusammensetzung
EP4268816B1 (en) * 2020-12-23 2026-03-25 Sumitomo Pharma Co., Ltd. Oral solid preparation

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4600579A (en) * 1983-06-07 1986-07-15 Mallinckrodt, Inc. N-acetyl-p-aminophenol compositions containing partially gelatinized starch and method for preparing same
US4551177A (en) 1984-04-23 1985-11-05 National Starch And Chemical Corporation Compressible starches as binders for tablets or capsules
US4609675A (en) 1984-08-17 1986-09-02 The Upjohn Company Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
US4837031A (en) 1987-09-17 1989-06-06 Mallinckrodt, Inc. Compositions containing ibuprofen
US5047246A (en) 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
US5104648A (en) 1989-02-02 1992-04-14 Mallinckrodt Specialty Chemicals Company High ibuprofen content granulations
US4911921A (en) 1989-02-02 1990-03-27 Mallinckrodt, Inc. High ibuprofen content granulations
JP2800953B2 (ja) 1990-07-06 1998-09-21 住友製薬株式会社 新規なイミド誘導体
US5605889A (en) 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
DE69624559T2 (de) 1995-02-28 2003-07-10 Aventis Pharmaceuticals Inc., Bridgewater Arzneizubereitungen für piperidinalkanolderivate
JP4022269B2 (ja) 1995-05-26 2007-12-12 協和醗酵工業株式会社 医薬組成物
CZ299018B6 (cs) 1997-10-20 2008-04-02 Dainippon Sumitomo Pharma Co., Ltd. Rychlerozpustný farmaceutický prípravek
JP4063386B2 (ja) * 1998-01-29 2008-03-19 キッセイ薬品工業株式会社 速放性経口医薬品組成物
US6150366A (en) 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
MX339071B (es) * 1999-03-31 2016-05-09 Janssen Pharmaceutica Nv Almidon pregelatinizado en una formulacion de liberacion controlada.
US6586617B1 (en) 1999-04-28 2003-07-01 Sumitomo Chemical Takeda Agro Company, Limited Sulfonamide derivatives
WO2001076557A1 (en) * 2000-04-10 2001-10-18 Sumitomo Pharmaceuticals Co., Ltd. Sustained release preparations
AU2001286237A1 (en) * 2000-09-22 2002-04-02 Sumitomo Pharmaceuticals Company, Limited Oral preparations with favorable disintegration characteristics
WO2002074743A1 (en) 2001-03-19 2002-09-26 Dainippon Pharmaceutical Co., Ltd. Aryl-substituted alicyclic compound and medical composition comprising the same
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
ES2685780T3 (es) * 2002-08-22 2018-10-11 Sumitomo Dainippon Pharma Co., Ltd. Agente para el tratamiento de esquizofrenia
MXPA05001707A (es) 2002-08-30 2005-04-19 Pharmacia Corp Formas de dosificacion farmaceutica solidas que presentan un perfil de liberacion de farmaco reproducible,.
JPWO2004078173A1 (ja) * 2003-02-05 2006-06-08 塩野義製薬株式会社 溶出性の改善された錠剤
AR045637A1 (es) 2003-09-12 2005-11-02 Amgen Inc Formulacion de disolucion rapida de un compuesto activo frente a los receptores de calcio
KR20060126688A (ko) 2003-12-09 2006-12-08 다이닛본 스미토모 세이야꾸 가부시끼가이샤 약물-함유 입자 및 그 입자를 함유하는 고형 제제
WO2006096439A2 (en) 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
SI1884242T1 (sl) 2005-05-26 2013-07-31 Dainippon Sumitomo Pharma Co., Ltd. Farmacevtski sestavek, ki vsebuje lurazidon

Also Published As

Publication number Publication date
FR14C0069I2 (fr) 2015-11-20
RU2398586C2 (ru) 2010-09-10
KR101380088B1 (ko) 2014-04-10
CN102048734A (zh) 2011-05-11
RU2398586C3 (ru) 2017-10-04
US8729085B2 (en) 2014-05-20
AU2006250340C1 (en) 2014-06-12
BRPI0611409B1 (pt) 2020-12-29
BRPI0611409A8 (pt) 2015-12-15
MX2007014872A (es) 2008-02-15
KR20130122019A (ko) 2013-11-06
BR122020005056B1 (pt) 2023-01-10
CY1114118T1 (el) 2016-06-22
HUS1400051I1 (hu) 2016-10-28
PL1884242T3 (pl) 2013-09-30
JP5285105B2 (ja) 2013-09-11
HK1108379A1 (en) 2008-05-09
US9907794B2 (en) 2018-03-06
EP2422783A1 (en) 2012-02-29
AU2006250340B2 (en) 2012-02-09
BR122020005056A8 (pt) 2022-11-22
US20150265611A1 (en) 2015-09-24
JPWO2006126681A1 (ja) 2008-12-25
CN101184489B (zh) 2011-01-19
BE2014C057I2 (cg-RX-API-DMAC10.html) 2025-12-10
ES2408687T3 (es) 2013-06-21
RU2007148997A (ru) 2009-07-10
EP1884242B1 (en) 2013-04-17
US20140235651A1 (en) 2014-08-21
KR20080012306A (ko) 2008-02-11
US8883794B2 (en) 2014-11-11
SI1884242T1 (sl) 2013-07-31
DK2422783T3 (en) 2015-05-11
NL300690I2 (nl) 2017-11-02
ES2535478T3 (es) 2015-05-12
EP2422783B1 (en) 2015-04-08
BR122020005056A2 (cg-RX-API-DMAC10.html) 2010-11-23
DK1884242T3 (da) 2013-05-06
PT1884242E (pt) 2013-05-21
CY2014039I1 (el) 2016-06-22
CY2014039I2 (el) 2016-06-22
BRPI0611409A2 (pt) 2010-11-23
US20150056284A1 (en) 2015-02-26
AU2006250340A1 (en) 2006-11-30
US9555027B2 (en) 2017-01-31
CA2606510C (en) 2014-07-22
CA2606510A1 (en) 2006-11-30
JP4733120B2 (ja) 2011-07-27
LU92550I2 (fr) 2015-11-02
US20090143404A1 (en) 2009-06-04
EP1884242A1 (en) 2008-02-06
WO2006126681A1 (ja) 2006-11-30
US20180161322A1 (en) 2018-06-14
JP2011126915A (ja) 2011-06-30
EP1884242A4 (en) 2009-07-01
CN101184489A (zh) 2008-05-21
BRPI0611409B8 (pt) 2021-05-25
FR14C0069I1 (fr) 2014-10-24
CN102048734B (zh) 2013-11-20

Similar Documents

Publication Publication Date Title
KR101380088B1 (ko) 약학 조성물
CA2824077C (en) Oral preparations with favorable disintegration characteristics
US11413295B2 (en) Oral preparation of obeticholic acid
EP3620156A1 (en) Composition having improved water solubility and bioavailability
JP7650033B2 (ja) ニトロキソリンを含む医薬組成物、ニトロキソリン経口固形錠剤、その調製方法、及びその使用
CN109875972B (zh) 一种奥美沙坦酯氨氯地平药物组合物
KR20180002977A (ko) 방출특성 및 생체이용률이 개선된 소라페닙 토실레이트를 포함하는 경구투여용 약제학적 조성물
CA3048968A1 (en) Oral pharmaceutical composition of lurasidone and preparation thereof
JP2017132724A (ja) アムロジピン含有被覆造粒物を含む配合口腔内崩壊錠
CA2671778A1 (en) Immediate release dosage form of bosentan and process of manufacturing such
HK1108379B (en) Pharmaceutical composition comprising lurasidone

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20180724

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

S17-X000 Non-exclusive voluntary license recorded

St.27 status event code: A-4-4-S10-S17-lic-X000

PA0101 Application to register extension of term of patent right by permit, etc.

St.27 status event code: A-4-4-G10-G18-tex-PA0101

Protection beyond ip right term event data comment text: Claim Total Quantity : 23, Claim Number : 1, 2, 3, 4, 5, 6, 8, 9, 10, 11, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, Period Limitation Text : 1826, Comment Text : 5155, 5156, 5157, 5158, 5159

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PE0702 Decision to register extension of term of patent right by permit, etc.

St.27 status event code: A-4-4-G10-G20-tex-PE0702

Protection beyond ip right term event data comment text: Claim Total Quantity : 23, Claim Number : 1, 2, 3, 4, 5, 6, 8, 9, 10, 11, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, Period Limitation Text : 1826, Comment Text : 5155, 5156, 5157, 5158, 5159

PJ0206 Trial to confirm the scope of a patent

St.27 status event code: A-5-5-V10-V11-apl-PJ0206

V11 Administrative appeal requested

Free format text: ST27 STATUS EVENT CODE: A-5-5-V10-V11-APL-PJ0206 (AS PROVIDED BY THE NATIONAL OFFICE)

PJ0206 Trial to confirm the scope of a patent

St.27 status event code: A-5-5-V10-V11-apl-PJ0206

V11 Administrative appeal requested

Free format text: ST27 STATUS EVENT CODE: A-5-5-V10-V11-APL-PJ0206 (AS PROVIDED BY THE NATIONAL OFFICE)

PJ0206 Trial to confirm the scope of a patent

St.27 status event code: A-5-5-V10-V11-apl-PJ0206

V11 Administrative appeal requested

Free format text: ST27 STATUS EVENT CODE: A-5-5-V10-V11-APL-PJ0206 (AS PROVIDED BY THE NATIONAL OFFICE)

PJ1301 Trial decision

St.27 status event code: A-5-5-V10-V15-crt-PJ1301

Decision date: 20260331

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 1552033

Appeal request date: 20260107

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2026100000035

Decision date: 20260331

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 1552033

Appeal request date: 20260107

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2026100000033

Decision date: 20260331

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 1552033

Appeal request date: 20260106

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2026100000021

Decision date: 20260331

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 1552033

Appeal request date: 20251224

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2025100003909

V15 Decision substituted

Free format text: ST27 STATUS EVENT CODE: A-5-5-V10-V15-CRT-PJ1301 (AS PROVIDED BY THE NATIONAL OFFICE); DECISION IDENTIFIER: 2026100000035; DECISION AUTHORITY: OFFICE APPEAL BOARD, APPEAL KIND CATEGORY : CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE

Free format text: ST27 STATUS EVENT CODE: A-5-5-V10-V15-CRT-PJ1301 (AS PROVIDED BY THE NATIONAL OFFICE); DECISION IDENTIFIER: 2026100000033; DECISION AUTHORITY: OFFICE APPEAL BOARD, APPEAL KIND CATEGORY : CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE

Free format text: ST27 STATUS EVENT CODE: A-5-5-V10-V15-CRT-PJ1301 (AS PROVIDED BY THE NATIONAL OFFICE); DECISION IDENTIFIER: 2026100000021; DECISION AUTHORITY: OFFICE APPEAL BOARD, APPEAL KIND CATEGORY : CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE

Free format text: ST27 STATUS EVENT CODE: A-5-5-V10-V15-CRT-PJ1301 (AS PROVIDED BY THE NATIONAL OFFICE); DECISION IDENTIFIER: 2025100003909; DECISION AUTHORITY: OFFICE APPEAL BOARD, APPEAL KIND CATEGORY : CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE

PJ1301 Trial decision

St.27 status event code: A-5-5-V10-V15-crt-PJ1301

Decision date: 20260401

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 1552033

Appeal request date: 20260107

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2026100000042

Decision date: 20260401

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 1552033

Appeal request date: 20260107

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2026100000040

Decision date: 20260401

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 1552033

Appeal request date: 20260107

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2026100000039

V15 Decision substituted

Free format text: ST27 STATUS EVENT CODE: A-5-5-V10-V15-CRT-PJ1301 (AS PROVIDED BY THE NATIONAL OFFICE); DECISION IDENTIFIER: 2026100000042; DECISION AUTHORITY: OFFICE APPEAL BOARD, APPEAL KIND CATEGORY : CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE

Free format text: ST27 STATUS EVENT CODE: A-5-5-V10-V15-CRT-PJ1301 (AS PROVIDED BY THE NATIONAL OFFICE); DECISION IDENTIFIER: 2026100000040; DECISION AUTHORITY: OFFICE APPEAL BOARD, APPEAL KIND CATEGORY : CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE

Free format text: ST27 STATUS EVENT CODE: A-5-5-V10-V15-CRT-PJ1301 (AS PROVIDED BY THE NATIONAL OFFICE); DECISION IDENTIFIER: 2026100000039; DECISION AUTHORITY: OFFICE APPEAL BOARD, APPEAL KIND CATEGORY : CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE